Publikation

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.

Wissenschaftlicher Artikel/Review - 08.05.2024

Bereiche
PubMed
DOI
Kontakt

Zitation
Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolaney S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. Ann Oncol 2024
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Ann Oncol 2024
Veröffentlichungsdatum
08.05.2024
eISSN (Online)
1569-8041
Kurzbeschreibung/Zielsetzung

In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC) with disease progression on prior endocrine therapy (ET). In MONARCH 3, the addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for HR+, HER2- ABC significantly improved PFS. Here, we present the prespecified final OS results for MONARCH 3.